Crinetics Pharmaceuticals Inc. (CRNX) has a key regulatory event coming up next month, which has the potential to significantly impact its stock price.
The company's lead asset is Paltusotine, the first once-daily, oral, selectively targeted somatostatin receptor type 2 agonist in development for the proposed treatment of people with acromegaly.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com